Form 4: Rhythm Pharmaceuticals Executive Exercises Options and Sells Shares
SEC Form 4 Filing
Pamela J. Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals, executed stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Pamela J. Cramer, Chief Human Resources Officer at Rhythm Pharmaceuticals, engaged in transactions involving the company's stock on April 8, 2025.
- She exercised stock options to acquire 14,060 shares at $6.80 and 6,700 shares at $27.35.
- Cramer also sold 6,430 shares at a weighted average price of $58.3562, 600 shares at $59, 6,700 shares at $60, and 7,030 shares at $62.
- These sales were executed under a Rule 10b5-1 trading plan adopted on December 16, 2024.
- Following these transactions, Cramer directly owns 19,209 shares of Rhythm Pharmaceuticals.
- She also holds options to purchase 42,190 shares at $6.80 and 20,100 shares at $27.35.
Sentiment
Score: 5
Explanation: The document reflects routine executive stock transactions. The use of a 10b5-1 plan suggests a neutral, pre-planned approach. There is no indication of unusual or concerning activity.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects. The use of a 10b5-1 plan suggests a pre-arranged strategy to avoid accusations of insider trading.
Comparison to Industry Standards
- Executive compensation packages often include stock options to align management's interests with those of shareholders.
- Rule 10b5-1 trading plans are a standard practice for corporate insiders to sell shares without being accused of acting on non-public information.
- The vesting schedules of the options (16 substantially equal installments upon completion of each three full months of successive service) are typical for employee stock option plans.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership.
- The transactions do not appear to have a significant impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2022-02-09 | Stock options granted at $6.80, vesting in 16 equal installments over three-month periods. |
| 2023-02-01 | Stock options granted at $27.35, vesting in 16 equal installments over three-month periods. |
| 2024-12-16 | Rule 10b5-1 trading plan adopted by Pamela J. Cramer. |
| 2025-04-08 | Date of stock option exercises and share sales. |
| 2032-02-08 | Expiration date of stock options granted on February 9, 2022. |
| 2033-01-31 | Expiration date of stock options granted on February 1, 2023. |
| 2025-04-10 | Date of Form 4 filing. |
Keywords
Rhythm Pharmaceuticals, RYTM, Pamela J. Cramer, Stock Options, Share Sales, Form 4, Rule 10b5-1, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.